Why Ionis (IONS) Stock Crashed Monday Even After Beating Earnings

2 hours ago 10

TLDR

Ionis (IONS) stock fell about 28% to $28.15 on Monday, its worst day since May 2016.
The company cut its 2026 Tryngolza sales outlook to about $50 million from $100 million to $110 million.
Third-quarter revenue hit $243 million, well above the $178.2 million analysts expected.
Full-year revenue guidance of $875 million to $900 million was reaffirmed.
The stock is down roughly 63% for the year.

Ionis (IONS) stock took a hard hit Monday after the drugmaker cut its sales outlook for Tryngolza. The stock dropped about 28% to $28.15, according to Dow Jones Market Data. That puts it on track for its worst single-day percentage drop since May 26, 2016.

IONS Stock Card
Ionis Pharmaceuticals, Inc., IONS

The selloff came even as the S&P 500, Dow Jones and Nasdaq all traded higher. So this was a company problem, not a market one.

$IONS Q3 2026 earnings: Ionis cuts its Tryngolza sales plan while Dawnzera grows

Ionis Pharmaceuticals, a developer of genetic medicines for rare and heart diseases, saw its main drug launch stumble while partner payments and a second launch filled the gap. Third-quarter revenue… pic.twitter.com/ERCoAYtStY

— Finsee (@Finsee_main) November 9, 2026

Ionis now expects Tryngolza to bring in about $50 million this year. Its earlier range was $100 million to $110 million. That is a cut of roughly 52% at the midpoint.

Why the Tryngolza Cut Stung

Management said the launch has ramped up more slowly than planned. Tryngolza targets severe hypertriglyceridemia and familial chylomicronemia syndrome. The drug aims to lower severe blood fats and help prevent pancreatitis.

The company also said it expects European approval later this year. That news was overshadowed by the guidance cut.

The weak outlook buried what was otherwise a solid quarter. Revenue rose 55% from a year earlier to $243 million. Wall Street had called for just $178.2 million.

The loss was 66 cents a share. Analysts polled expected a wider loss of $1.01 a share. The net loss narrowed 15% to $110 million.

Ionis kept its full-year revenue guidance at $875 million to $900 million. It also held its non-GAAP operating loss and cash guidance. FactSet analysts, however, were looking for about $922.4 million.

Other drugs helped fill the gap. Dawnzera, which aims to prevent swelling attacks in hereditary angioedema, brought in $37 million in the third quarter. Ionis said it is on track for its $110 million to $120 million full-year target, with international rollouts underway.

There was also a launch update on Zanvastro. The drug is meant to slow the progression of Alexander disease. The first patients are now receiving it after approval.

Not everything looked rosy, though. Cash fell to $1.9 billion from $2.7 billion. A senior executive’s share sale was also disclosed, which added to the negative mood.